# Dikhnah Alshehri, et al.: Gut microbiota in IBD therapy

# References

1. Schäffler H, Herlemann DP, Alberts C, Kaschitzki A, Bodammer P, Bannert K, et al. Mucosa-attached bacterial community in Crohn’s disease coheres with the clinical disease activity index. Environ Microbiol Rep 2016;8(5):614-21. https://doi.org/10.1111/1758-2229.12411.
2. Laubitz D, Harrison CA, Midura-Kiela MT, Ramalingam R, Larmonier CB, Chase JH, et al. Reduced epithelial Na+/H+ exchange drives gut microbial dysbiosis and promotes inflammatory response in T cell-mediated murine colitis. PLoS One 2016;11(4):e0152044. https://doi.org/10.1371/journal.pone.0152044.
3. Tchaptchet S, Fan TJ, Goeser L, Schoenborn A, Gulati AS, Sartor RB, et al. Inflammation-induced acid tolerance genes gadAB in luminal commensal Escherichia coli attenuate experimental colitis. Infection Immun 2013;81(10):3662-71. https://doi.org/10.1128/iai.00355-13.
4. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 2004;127(2):412-21. https://doi.org/10.1053/j.gastro.2004.04.061.
5. Liu Y, van Kruiningen HJ, West AB, Cartun RW, Cortot A, Colombel JF. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn’s disease. Gastroenterology 1995;108(5):1396-404. https://doi.org/10.1016/0016-5085(95)90687-8.
6. Atreya R, Neurath MF. Current and future targets for mucosal healing in inflammatory bowel disease. Visceral Med 2017;33(1):82-8. https://doi.org/10.1159/000458006.
7. Hansen JJ, Sartor RB. Therapeutic manipulation of the microbiome in IBD: Current results and future approaches. Curr Treatment Options Gastroenterol 2015;13(1):105-20. https://doi.org/10.1007/s11938-014-0042-7.
8. Cénit MC, Matzaraki V, Tigchelaar EF, Zhernakova A. Rapidly expanding knowledge on the role of the gut microbiome in health and disease. Biochim Biophys Acta 2014;1842(10):1981-92. https://doi.org/10.1016/j.bbadis.2014.05.023.
9. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010;28:573-621. https://doi.org/10.1146/annurev-immunol-030409-101225.
10. Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, et al. Systematic review with meta-analysis: Real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol 2018;53(9):1048-64. https://doi.org/10.1007/s00535-018-1480-0.
11. Mosli MH, Rivera-Nieves J, Feagan BG. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: Current and future prospects. Drugs 2014;74(3):297-311. https://doi.org/10.1007/s40265-013-0176-2.
12. Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: Data from the EXTEND trial. Gastroenterology 2012;142(5):1102-11. https://doi.org/10.1053/j.gastro.2012.01.035.
13. D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132(2):763-86. https://doi.org/10.1053/j.gastro.2006.12.038.
14. Kwapisz L, Mosli M, Chande N, Yan B, Beaton M, Micsko J, et al. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study. Saudi J Gastroenterol 2015;21(6):360-6. https://doi.org/10.4103/1319-3767.170948.
15. Malamut G, Afchain P, Verkarre V, Lecomte T, Amiot A, Damotte D, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of Type I with Type II. Gastroenterology 2009;136(1):81-90. https://doi.org/10.1053/j.gastro.2008.09.069.
16. Mosli MH, Feagan BG, Sandborn WJ, D’Haens G, Behling C, Kaplan K, et al. Histologic evaluation of ulcerative colitis: A systematic review of disease activity indices. Inflamm Bowel Dis 2014;20(3):564-75. https://doi.org/10.1097/01.mib.0000437986.00190.71.
17. Mosli MH, Feagan BG, Zou G, Sandborn WJ, D’Haens G, Khanna R, et al. Reproducibility of histological assessments of disease activity in UC. Gut 2015;64(11):1765-73. https://doi.org/10.1136/gutjnl-2014-307536.
18. Jairath V, Peyrin-Biroulet L, Zou G, Mosli M, Casteele NV, Pai RK, et al. Responsiveness of histological disease activity indices in ulcerative colitis: A post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut 2019;68(7):1162-8. https://doi.org/10.1136/gutjnl-2018-316702.
19. Brennan F, Maini R, Feldmann M. TNFα-a pivotal role in rheumatoid arthritis? Rheumatology 1992;31(5):293-8. https://doi.org/10.1093/rheumatology/31.5.293.
20. Yoshihara T, Shinzaki S, Kawai S, Fujii H, Iwatani S, Yamaguchi T, et al. Tissue drug concentrations of anti-tumor necrosis factor agents are associated with the long-term outcome of patients with Crohn’s disease. Inflamm Bowel Dis 2017;23(12):2172-9. https://doi.org/10.1097/mib.0000000000001260.
21. Poggi A, Benelli R, Venè R, Costa D, Ferrari N, Tosetti F, et al. Human gut-associated natural killer cells in health and disease. Front Immunol 2019;10:961. https://doi.org/10.3389/fimmu.2019.00961.
22. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141(4):1194-201. https://doi.org/10.1053/j.gastro.2011.06.054.
23. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362(15):1383-95. https://doi.org/10.1056/nejmoa0904492.
24. Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages. Gastroenterology 2011;141(6):2026-38. https://doi.org/10.1053/j.gastro.2011.08.032.
25. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):2462-76. https://doi.org/10.1056/nejmoa050516.
26. Sandborn WJ, Colombel JF, D’Haens G, Van Assche G, Wolf D, Kron M, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: Subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013;37(2):204-13. https://doi.org/10.1111/apt.12145.
27. Magnusson MK, Strid H, Sapnara M, Lasson A, Bajor A, Ung KA, et al. Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J Crohns Colitis 2016;10(8):943-52. https://doi.org/10.1093/ecco-jcc/jjw051.
28. Varela E, Manichanh C, Gallart M, Torrejón A, Borruel N, Casellas F, et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther 2013;38(2):151-61. https://doi.org/10.1111/apt.12365.
29. Li D, Yu G, Hu H, Li X, Wang Y, Xiao Y, et al. Characteristics of faecal microbiota in paediatric Crohn’s disease and their dynamic changes during infliximab therapy. J Crohns Colitis 2017;12(3):337-46. https://doi.org/10.1093/ecco-jcc/jjx153.
30. Ben-Horin S, Mao R, Chen M. Optimizing biologic treatment.

Bosn J Basic Med Sci. 2021;21(3):270-283 www.bjbms.org